Literature DB >> 266732

Postulated deficiency of hepatic heme and repair by hematin infusions in the "inducible" hepatic porphyrias.

C J Watson, C A Pierach, I Bossenmaier, R Cardinal.   

Abstract

There is compelling, indirect evidence of hepatic heme deficiency due primarily to the respective genetic errors of the three inducible hepatic porphyrias, acute intermittent porphyria, porphyria variegata, and hereditary coproporphyria. The induction is enhanced by exogenous inducers such as barbiturate, estrogens and other "porphyrogenic" chemicals and factors, including glucose deprivation. The newer knowledge of the induction of delta-aminolevulinic acid synthetase [delta-aminolevulinate synthase; succinyl--CoA:glycine C-succinyltransferase (decarboxylating), EC 2.3.1.37] in relation to inadequate heme, and repression by heme, stimulated early trials of hematin infusions to overcome the acute relapse in the foregoing inducible porphyrias. Recently this experience has been considerably expanded, 143 infusions of hematin having been given in 22 cases. Studies of the effect on the serum concentrations of delta-aminolevulinic acid and porphobilinogen have shown a highly significant decline, often to 0, especially of delta-aminolevulinic acid. A distinct relationship to the clinical severity of the attack has been evident in the frequency and magnitude of decline of serum delta-aminolevulinic acid and porphobilinogen. This was regularly associated with objective clinical improvement.

Entities:  

Mesh:

Substances:

Year:  1977        PMID: 266732      PMCID: PMC431086          DOI: 10.1073/pnas.74.5.2118

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  22 in total

1.  PRESENT STATUS OF THE EHRLICH ALDEHYDE REACTION FOR URINARY PORPHOBILINOGEN.

Authors:  C J WATSON; L TADDEINI; I BOSSENMAIER
Journal:  JAMA       Date:  1964-11-09       Impact factor: 56.272

2.  THE EFFECT OF CARBOHYDRATE FEEDING ON THE INDUCTION OF DELTA-AMINOLEVULINIC ACID SYNTHETASE.

Authors:  D P TSCHUDY; F H WELLAND; A COLLINS; G HUNTER
Journal:  Metabolism       Date:  1964-05       Impact factor: 8.694

3.  ACUTE INTERMITTENT PORPHYRIA: THE FIRST "OVERPRODUCTION DISEASE" LOCALIZED TO A SPECIFIC ENZYME.

Authors:  D P TSCHUDY; M G PERLROTH; H S MARVER; A COLLINS; G HUNTER; M RECHCIGL
Journal:  Proc Natl Acad Sci U S A       Date:  1965-04       Impact factor: 11.205

4.  Increase in activity of alpha-aminolevulinic acid synthetase in liver mitochondria induced by feeding of 3,5-dicarbethoxy-1,4-dihydrocollidine.

Authors:  S GRANICK; G URATA
Journal:  J Biol Chem       Date:  1963-02       Impact factor: 5.157

5.  Acute porphyria: a neuropsychiatric and biochemical study.

Authors:  B ACKNER; J E COOPER; C H GRAY; M KELLY
Journal:  J Psychosom Res       Date:  1962 Jan-Mar       Impact factor: 3.006

6.  Effect of hematin in acute porphyric relapse.

Authors:  C J Watson; G J Dhar; I Bossenmaier; R Cardinal; Z J Petryka
Journal:  Ann Intern Med       Date:  1973-07       Impact factor: 25.391

7.  Enzymatic defects in hepatic porphyria. Preliminary observations in patients with porphyria cutanea tarda and variegate porphyria.

Authors:  N R Pimstone; G Blekkenhorst; L Eales
Journal:  Enzyme       Date:  1973

8.  The primary enzyme defect in hereditary coproporphyria.

Authors:  G H Elder; J O Evans; N Thomas
Journal:  Lancet       Date:  1976-12-04       Impact factor: 79.321

9.  Onset of manifestations of hepatic porphyria in relation to the influence of female sex hormones.

Authors:  T S Zimmerman; J M McMillin; C J Watson
Journal:  Arch Intern Med       Date:  1966-09

10.  Repression of the overproduction of porphyrin precursors in acute intermittent porphyria by intravenous infusions of hematin.

Authors:  H L Bonkowsky; D P Tschudy; A Collins; J Doherty; I Bossenmaier; R Cardinal; C J Watson
Journal:  Proc Natl Acad Sci U S A       Date:  1971-11       Impact factor: 11.205

View more
  15 in total

Review 1.  The acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Transl Gastroenterol Hepatol       Date:  2021-04-05

2.  Delta-Aminolaevulinic acid and amino acid neurotransmitters.

Authors:  M J Brennan; R C Cantrill
Journal:  Mol Cell Biochem       Date:  1981-08-11       Impact factor: 3.396

3.  Hematin therapy in porphyric attacks.

Authors:  C A Pierach; I Bossenmaier; R Cardinal; M Weimer; C J Watson
Journal:  Klin Wochenschr       Date:  1980-08-15

4.  Studies in porphyria. VII. Induction of uroporphyrinogen-I synthase and expression of the gene defect of acute intermittent porphyria in mitogen-stimulated human lymphocytes.

Authors:  S Sassa; G L Zalar; A Kappas
Journal:  J Clin Invest       Date:  1978-02       Impact factor: 14.808

5.  Secretion of haem by hepatic parenchymal cells.

Authors:  D M Bissell; H H Liem; U Muller-Eberhard
Journal:  Biochem J       Date:  1979-12-15       Impact factor: 3.857

Review 6.  Enzymatic defects of hereditary porphyrias: an explanation of dominance at the molecular level.

Authors:  G Romeo
Journal:  Hum Genet       Date:  1977-12-23       Impact factor: 4.132

7.  The role of cytosolic proteins in the intracellular transport of haem in rat liver. A dual-label approach.

Authors:  D M Davies; H H Liem; E F Johnson; U Muller-Eberhard
Journal:  Biochem J       Date:  1982-01-15       Impact factor: 3.857

8.  Incorporation of haemoglobin haem into the rat hepatic haemoproteins tryptophan pyrrolase and cytochrome P-450.

Authors:  J F Wyman; J L Gollan; W Settle; G C Farrell; M A Correia
Journal:  Biochem J       Date:  1986-09-15       Impact factor: 3.857

9.  Bovine protoporphyria: documentation of autosomal recessive inheritance and comparison with the human disease through measurement of heme synthase activity.

Authors:  J R Bloomer; K O Morton; R J Reuter; G R Ruth
Journal:  Am J Hum Genet       Date:  1982-03       Impact factor: 11.025

Review 10.  Novel treatment options for acute hepatic porphyrias.

Authors:  Bruce Wang
Journal:  Curr Opin Gastroenterol       Date:  2021-05-01       Impact factor: 2.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.